<p>Phosphopeptides shown are a selection where a confident assessment of a common decrease or increase in 4 or more of the 6 oncogenes has been found. To be included the peptide must be called as changing in the majority of experiments in which it is quantified and must not be called as changing in the internal replicate. To be called as changing a peptide must have a ratio outside the range of which 95% of phosphopeptide ratios for the internal replicate are found. The ratio column contains an average of the ratios across multiple experiments. This is supported by the averaged confidence which indicates how closely the experiments agree. The confidence for each experiment is the proportion of ratios in the internal replicate that the ratio...
<p>Phosphorylation level of each phosphopeptide is represented in a list of ratios. We used the pept...
<p>Proteins significantly different from the control within a given biological replicate are indicat...
<p>Here are examples of phosphopeptides that contain activator and inhibitor phosphorylation sites o...
<p>Proteins shown are those where a confident assessment of a common decrease or increase in 4 or mo...
<p>Changes in phosphorylation abundance are represented as heatmaps from 5 replicate experiments as ...
<p>List of phosphopeptides that show significant changes in abundance in response to CSPG treatment ...
<p>List of the 61 differentially expressed proteins identified in pooled fractions F1, using a 0.95 ...
<p>List of the 69 differentially expressed proteins identified in pooled fractions F2, using a 0.95 ...
Data represented here was obtained from merging two independent biological replicates.</p
<p>Total peptide detected is represented by each full bar in (A), with the white portion representin...
<p>The percentage of sequenced peptides (expressed as the percentage of the total signal intensity) ...
<p>Proteins with changed expressions in the N clone individuals which had been treated with CP, comp...
Proteins with nominal evidence for change (unadjusted p<0.05) during treatment of the protein array ...
<p>All PS, overall number of protein spots with significant differences; PS, number of protein spots...
<p>N/a, not applicable, indicates that the phosphopeptides were not detected in this group and were ...
<p>Phosphorylation level of each phosphopeptide is represented in a list of ratios. We used the pept...
<p>Proteins significantly different from the control within a given biological replicate are indicat...
<p>Here are examples of phosphopeptides that contain activator and inhibitor phosphorylation sites o...
<p>Proteins shown are those where a confident assessment of a common decrease or increase in 4 or mo...
<p>Changes in phosphorylation abundance are represented as heatmaps from 5 replicate experiments as ...
<p>List of phosphopeptides that show significant changes in abundance in response to CSPG treatment ...
<p>List of the 61 differentially expressed proteins identified in pooled fractions F1, using a 0.95 ...
<p>List of the 69 differentially expressed proteins identified in pooled fractions F2, using a 0.95 ...
Data represented here was obtained from merging two independent biological replicates.</p
<p>Total peptide detected is represented by each full bar in (A), with the white portion representin...
<p>The percentage of sequenced peptides (expressed as the percentage of the total signal intensity) ...
<p>Proteins with changed expressions in the N clone individuals which had been treated with CP, comp...
Proteins with nominal evidence for change (unadjusted p<0.05) during treatment of the protein array ...
<p>All PS, overall number of protein spots with significant differences; PS, number of protein spots...
<p>N/a, not applicable, indicates that the phosphopeptides were not detected in this group and were ...
<p>Phosphorylation level of each phosphopeptide is represented in a list of ratios. We used the pept...
<p>Proteins significantly different from the control within a given biological replicate are indicat...
<p>Here are examples of phosphopeptides that contain activator and inhibitor phosphorylation sites o...